Valeant pays $65M upfront for U.S. rights to Eisai's Targretin

02/22/2013 | Genetic Engineering & Biotechnology News

Eisai has sold the U.S. rights to Targretin capsules and 1% gel to Valeant Pharmaceuticals for $65 million plus possible milestone fees. Valeant will handle the new drug application and other regulatory obligations in the U.S. Targretin, or bexarotene, capsules and gel are used to treat patients with skin problems associated with cutaneous T-cell lymphoma who failed to respond to at least one systemic treatment.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA